subgroups of CRC patients
European CRC patients
distinct molecular subtypes
molecular defined subtypes of colorectal cancer
distinct prognosis
molecular diagnostic assays
C-type signature
present gene expression profiles
equivalent gene expression patterns
studies
cancer types
advantage of molecular classification
heterogeneous disease
MSI
drug response phenotypes
poor-risk prognosis
single platform
beginning of treatment
targeted therapies
current therapies
primary endpoint
liquid biopsies
combination of chemotherapy
primary objectives
retrospective analysis
Mutation analysis
specific treatment strategies
different biological processes
routine FFPE tumour biopsies
immunotherapeutic anti-PD-L1 drug
stage single arm multi-centre open-label phase
CMS4
solid preclinical evidence
MoTriColor
sound scientific rationale
progression-free survival
safety
MPDL3280A
significant impact
deregulated signalling pathways
experimental treatments
tolerability
clinical efficacy
TGF-Î²R inhibitor
biomarkers
LY2157299
guided trials
BRAF mutant
monitoring
basis
bevacizumab
vinorelbine
responses
selected populations
project outcomes
overall objective
BRAFm
approaches
results